Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.
about
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmissionQuetiapine versus other atypical antipsychotics for schizophreniaDetection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatmentUsing internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationThe comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?Antipsychotic drugs and obesity.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label studyFactors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disordersTrabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female MiceSystematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-upAntipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndromeMetabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsMetabolic syndrome in schizophrenia.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Treatment strategies for dosing the second generation antipsychotics.Weight gain associated with taking psychotropic medication: an integrative review.Lipid effects of psychiatric medications.Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.Experimental drugs for bipolar psychosis.Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Atypical antipsychotics for the treatment of ICU delirium.Low Density Lipoprotein Receptor-Related Protein and Apolipoprotein E Expression is Altered in Schizophrenia.Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.Identification and counseling for obesity among children on psychotropic medications in ambulatory settings.
P2860
Q23913269-80457983-22B5-45A4-9A30-B33364BEE789Q24202427-F945F37A-F0FC-46B8-894D-1F50EFA84769Q26864342-745E3135-7FDC-4555-9CF3-8004818AF734Q28541531-BA0E485A-1E7C-437D-93B7-B07BF1B1E5F6Q30501289-7494D07F-A585-448F-A004-E9D444580883Q30736365-B713D109-C4EC-42EA-BE48-BB6DA7004820Q33622056-433B56A7-2F3B-4A06-B387-292112CF793EQ33968686-7D78DECA-6779-403F-81CE-D713E90ACAA3Q34181934-4FB33BE4-3DB8-4963-B88B-987B6202FFC5Q34484974-F3CE7E95-0097-47A9-9ADC-CAB08E1D35DDQ34634393-FC1E01A4-FFF8-43D8-B279-4AF2B2D02B56Q34648940-D81DA031-D6DF-4646-9ABC-DE5CEE17ADB0Q35156543-6FDEC3BA-7665-4503-9727-4C94D0FBCAABQ35191252-5D0A8778-9B03-410C-B94B-D0FC50FA2F2FQ35334500-53EFC2AF-7797-4540-8E8D-E95269785504Q35680962-23CBDC2D-58F6-46DF-9592-0354C38D840EQ35754726-6AA336B4-4918-42B9-9A64-42B17FEACA9AQ35763638-523AEAFF-A76F-4811-BAA1-968146EFA444Q36034676-AD58806D-96A7-4468-9879-DE8B0320F5C5Q36063735-1A84A55D-A721-43E0-8C41-86E472657F85Q36621041-15B95868-DE35-4E92-82F4-6D08DCEB59F4Q37043479-F2503471-AD76-449D-A417-C9D46DC82E22Q37102229-08DEB916-6FCD-43C3-9AB5-372012FB8A2EQ37110540-AA0DF419-19FA-4D5A-B4C2-A8A29D57252DQ37236162-C0A0A84E-260F-4E8C-BB9F-CE06F4FA86D6Q37290165-DB27E0DE-887B-4854-81CC-9AFA8B4294ACQ37760926-F035F88C-4604-458B-9B85-DF555E44D493Q37852818-DEA77C8A-B003-4E72-B9B4-6189DD7C4DDBQ37865068-689C4A34-4827-4B74-8081-8E344A550E89Q38066118-9CBA2DBF-6916-4697-9051-08D7AC8E9F7DQ38473090-A36BBED6-3AA5-475C-94C6-1EDD32357D27Q38660754-73750538-FC83-49BD-A4D1-9E772260588AQ38995982-60FA4AEA-32FC-4556-93D7-07714FBCBF20Q39209607-292C9F61-462F-457B-9AF8-1EB161719E86Q39767297-9068320E-AA27-4355-85A9-02F2E6B202EFQ41771932-7DD77075-2590-4E7C-B199-EC51EEE00512Q42427644-CC8E3AA8-6E88-4568-BD86-7869B05103A3Q43613438-C19A7FE4-3B10-4D59-9278-0E544AB7B75BQ43691248-1F711E17-D029-4E16-8984-6650D74BBEECQ44223285-1CFF6C16-137C-46EE-9F60-D22695830E8C
P2860
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Metabolic profiles of second-g ...... findings from the CAFE study.
@en
Metabolic profiles of second-g ...... findings from the CAFE study.
@nl
type
label
Metabolic profiles of second-g ...... findings from the CAFE study.
@en
Metabolic profiles of second-g ...... findings from the CAFE study.
@nl
prefLabel
Metabolic profiles of second-g ...... findings from the CAFE study.
@en
Metabolic profiles of second-g ...... findings from the CAFE study.
@nl
P2093
P1476
Metabolic profiles of second-g ...... findings from the CAFE study.
@en
P2093
CAFE Investigators
Diana O Perkins
Jayendra K Patel
Jeffrey A Lieberman
Joseph P McEvoy
Peter F Buckley
Robert M Hamer
Sandra Woolson
P356
10.1016/J.SCHRES.2009.03.025
P407
P577
2009-04-26T00:00:00Z